C2 monitoring of cyclosporine in de novo liver transplant recipients: The clinician's perspective

Federico Villamil, Stephen Pollard – 20 April 2004 – Adjusting cyclosporine (CsA) dose based on blood concentration at 2 hours after dose (C2) has been shown in prospective clinical trials to reduce the risk of rejection compared with conventional trough monitoring. In addition, it provides equivalent efficacy to tacrolimus in liver transplant patients, with a favorable safety profile. Target C2 should be defined on an individual basis depending on adjunctive therapy and the level of exposure required.

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa‐2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain rea

Guy W. Neff, Christopher B. O'Brien, Robert Cirocco, Marzia Montalbano, Maria de Medina, Phillip Ruiz, Amr S. Khaled, Pablo A. Bejarano, Kamran Safdar, Mary A. Hill, Andreas G. Tzakis, Eugene R. Schiff – 20 April 2004 – The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known.

Hepatocellular carcinoma in HCV‐infected patients awaiting liver transplantation: Genes involved in tumor progression

Valeria R. Mas, Daniel G. Maluf, Richard Stravitz, Catherine I. Dumur, Bradly Clark, Cheryl Rodgers, Andrea Ferreira‐Gonzalez, Robert A. Fisher – 20 April 2004 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death in the world. The present study aimed to investigate the genes involved in viral carcinogenesis and tumor progression in liver transplant recipients with hepatitis C virus (HCV) and HCC.

New national liver transplant allocation policy: Is the regional review board process fair?

Michael D. Voigt, Bridget Zimmerman, Daniel A. Katz, Stephen C. Rayhill – 20 April 2004 – Experienced transplant professionals may predict mortality better, in highly selected cirrhotic patients referred for accelerated listing to regional review boards, than the (Pediatric) Model for End‐Stage Liver Disease score. However, these requests are often denied. We wished to establish if (1) such denials increase mortality and (2) referring physicians predict mortality better than the score.

The development of de novo hepatocellular carcinoma in patients on a liver transplant list: Frequency, size, and assessment of current screening methods

David H. Van Thiel, Sherri Yong, S. David Li, Marc Kennedy, John Brems – 20 April 2004 – Chronic end stage liver disease is the most frequent indication for liver transplantation. Individuals with end stage cirrhosis, and therefore individuals on liver transplant lists, are at increased risk of developing a hepatic cancer.

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

Victor I. Machicao, Murli Krishna, Hugo Bonatti, Bashar A. Aqel, Justin H. Nguyen, Stephen D. Weigand, Barry G. Rosser, Christopher Hughes, Rolland C. Dickson – 20 April 2004 – The natural history of allograft steatosis in hepatitis C (HCV)‐infected patients after liver transplantation (LT) is poorly understood. The aim of our study was to determine the relationship of allograft steatosis to HCV recurrence after LT. All patients undergoing LT at our center from March 1998 to December 2001 were included in the study.

Hepatic splenosis misinterpreted as hepatocellular carcinoma in cirrhotic patients referred for liver transplantation: Report of two cases

Giovan Giuseppe Di Costanzo, Francesco Paolo Picciotto, Giuseppina Marino Marsilia, Antonio Ascione – 20 April 2004 – Liver transplantation is one of the main therapeutic options for hepatocellular carcinoma (HCC) occurring in cirrhotic patients; an accurate diagnosis and staging of this cancer is crucial to selecting the candidates for this treatment. Although the best diagnostic strategy is debated, the guidelines proposed by the European Association for the Study of the Liver (EASL) are used by many centers.

Growth hormone/insulin‐like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study

Marco Bassanello, Elio Franco De Palo, Federica Lancerin, Alessandro Vitale, Rosalba Gatti, Umberto Montin, Francesco Antonio Ciarleglio, Marco Senzolo, Patrizia Burra, Alberto Brolese, Giacomo Zanus, Davide Francesco D'Amico, Umberto Cillo – 20 April 2004 – Many studies on cirrhotic patients have shown that insulin‐like growth factor 1 (IGF‐1) plasma levels are related to the severity of liver dysfunction. This result suggests that IGF‐1 is probably useful for monitoring liver function in the perioperative course of orthotopic liver transplantation (OLT).

Liver transplantation for neuroendocrine tumors: Progress and uncertainty

Barbara Rosado, Gregory J. Gores – 20 April 2004 – Metastases from neuroendocrine tumors (NET) of the gastrointestinal tract, carcinoids, and endocrine pancreatic tumors (EPT) can be limited to the liver for long periods and may have slow growth. The symptoms are often related to hormone overproduction, and debulking surgery—for example, liver resection—is recommended to achieve tumor remission or symptom palliation. If liver resection is not feasible, hepatectomy and orthotopic liver transplantation (OLT) have been proposed.

Subscribe to